<rss version="2.0"><channel><title>Yahoo! Finance: NVC.TO News</title><copyright>Copyright (c) 2016 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=nvc.to</link><description>Latest Financial News for NEOVASC INC</description><language>en-US</language><lastBuildDate>Tue, 20 Dec 2016 16:59:00 GMT</lastBuildDate><image><url>http://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif</url><title>Yahoo! Finance: NVC.TO News</title><link>http://finance.yahoo.com/q/h?s=nvc.to</link><width>144</width><height>45</height></image><item><title>IIROC Trading Halt - NVC</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/iiroc-trading-halt-nvc-165900327.html</link><description /><guid isPermaLink="false">yahoo_finance/1011695058</guid><pubDate>Tue, 20 Dec 2016 16:59:00 GMT</pubDate></item><item><title>IIROC Trading Halt - NVC</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/iiroc-trading-halt-nvc-165900712.html</link><description /><guid isPermaLink="false">yahoo_finance/1755169646</guid><pubDate>Tue, 20 Dec 2016 16:59:00 GMT</pubDate></item><item><title>Neovasc Regains Compliance with NASDAQ Listing Requirements</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-regains-compliance-nasdaq-listing-185600507.html</link><description>[PR Newswire] - VANCOUVER, Dec. 19, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) announced today that the Company has regained compliance with the listing requirements of The NASDAQ Stock Market LLC ("Nasdaq"). As previously reported, on July 5, 2016, Neovasc received a letter from Nasdaq notifying the Company that it was not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on The Nasdaq Capital Market.</description><guid isPermaLink="false">yahoo_finance/3958415822</guid><pubDate>Mon, 19 Dec 2016 18:56:00 GMT</pubDate></item><item><title>Neovasc Regains Compliance with NASDAQ Listing Requirements</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-regains-compliance-nasdaq-listing-185600277.html</link><description>[CNW Group] - Neovasc Regains Compliance with NASDAQ Listing Requirements</description><guid isPermaLink="false">yahoo_finance/3464058728</guid><pubDate>Mon, 19 Dec 2016 18:56:00 GMT</pubDate></item><item><title>Boston Scientific Acquires Neovasc to Boost Heart Business</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/boston-scientific-acquires-neovasc-boost-132401627.html</link><description /><guid isPermaLink="false">yahoo_finance/2739859664</guid><pubDate>Wed, 14 Dec 2016 13:24:01 GMT</pubDate></item><item><title>Boston Scientific Closes Acquisition of Advanced Biological Tissue Capabilities and Acquires Common Shares of Neovasc, Inc.</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/boston-scientific-closes-acquisition-advanced-120000813.html</link><description>[PR Newswire] - MARLBOROUGH, Mass., Dec. 13, 2016 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced the close of its acquisition of certain manufacturing assets and capabilities of the Neovasc, Inc., (NVCN) (NVC.TO) advanced biological tissue business. The two organizations announced a definitive agreement on December 2, 2016 for Boston Scientific to acquire the advanced biologic tissue capabilities and make a 15% equity investment in Neovasc, for a total of $75 million in cash. The common shares were acquired for investment purposes.</description><guid isPermaLink="false">yahoo_finance/3473028618</guid><pubDate>Tue, 13 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc and Boston Scientific Close US$75 Million Agreement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-boston-scientific-close-us-120000034.html</link><description>[CNW Group] - Neovasc and Boston Scientific Close US$75 Million Agreement</description><guid isPermaLink="false">yahoo_finance/2547157648</guid><pubDate>Tue, 13 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc and Boston Scientific Close US$75 Million Agreement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-boston-scientific-close-us-120000107.html</link><description>[PR Newswire] - VANCOUVER, Dec. 13, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced the close of its transaction with Boston Scientific Corporation (BSX). The two organizations announced a definitive agreement on December 2, 2016 for Boston Scientific to acquire Neovasc's advanced biologic tissue capabilities and certain manufacturing assets and make a 15% equity investment in Neovasc, for a total of US$75 million in cash. Under the terms of the asset purchase agreement Neovasc has been granted a license to the purchased assets and access to the sold facilities to allow it to continue its tissue and valve assembly activities for its remaining customers, and continue its own tissue-related programs, including advancing its mitral bioprosthesis valve Tiara&#8482; through its clinical and regulatory pathways.</description><guid isPermaLink="false">yahoo_finance/2210013257</guid><pubDate>Tue, 13 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc, Inc. :NVC-CA: Earnings Analysis: Q3, 2016 By the Numbers : December 9, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=13og95ro6/*http://www.capitalcube.com/blog/index.php/neovasc-inc-nvc-ca-earnings-analysis-q3-2016-by-the-numbers-december-9-2016/</link><description /><guid isPermaLink="false">yahoo_finance/4168946095</guid><pubDate>Fri, 09 Dec 2016 13:17:47 GMT</pubDate></item><item><title>Neovasc Provides Update on its Tiara&#8482; Mitral Valve Clinical Program</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-provides-tiara-mitral-valve-120000677.html</link><description>[CNW Group] - Neovasc Provides Update on its Tiara&#8482; Mitral Valve Clinical Program</description><guid isPermaLink="false">yahoo_finance/916082687</guid><pubDate>Tue, 06 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc Provides Update on its Tiara&#8482; Mitral Valve Clinical Program</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-provides-tiara-mitral-valve-120000310.html</link><description>[PR Newswire] - VANCOUVER, Dec. 6, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today provided an update on the clinical experience with its Tiara&#8482; transcatheter mitral valve. Tiara&#8482; is a novel transcatheter device designed to treat mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death. There have been no reported adverse events related to the valve performance. There have been no frame fractures, or any device performance issues observed with the Tiara&#8482; in any patient follow-up.</description><guid isPermaLink="false">yahoo_finance/548292199</guid><pubDate>Tue, 06 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Boston Scientific (BSX) Inks $75 Million Deal with Neovasc</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/boston-scientific-bsx-inks-75-131001751.html</link><description /><guid isPermaLink="false">yahoo_finance/3885651766</guid><pubDate>Mon, 05 Dec 2016 13:10:01 GMT</pubDate></item><item><title>Neovasc and Boston Scientific Reach US$75 Million Agreement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-boston-scientific-reach-us-120000841.html</link><description>[CNW Group] - Neovasc and Boston Scientific Reach US$75 Million Agreement</description><guid isPermaLink="false">yahoo_finance/1284239949</guid><pubDate>Fri, 02 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc and Boston Scientific Reach US$75 Million Agreement</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-boston-scientific-reach-us-120000849.html</link><description>[PR Newswire] - VANCOUVER, Dec. 2, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced that Boston Scientific Corporation (BSX), a global medical technology leader, has agreed to acquire Neovasc's tissue processing technology and facility for approximately US$67,909,800. Concurrently, Boston Scientific has committed to invest an additional US$7,090,200 in Neovasc for a 15% equity interest in the Company.</description><guid isPermaLink="false">yahoo_finance/1233513445</guid><pubDate>Fri, 02 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/boston-scientific-announces-agreement-acquire-120000893.html</link><description>[PR Newswire] - MARLBOROUGH, Mass., Dec. 2, 2016 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced a definitive agreement to acquire certain manufacturing assets and capabilities of the Neovasc, Inc., (NVCN) (NVC.TO) advanced biological tissue business, as well as a 15% equity stake in Neovasc, for a total of $75 million in cash. "We continually seek ways to optimize our manufacturing processes and enhance our product portfolio," said Ed Mackey, executive vice president, operations, Boston Scientific. The acquisition is expected to close by year-end 2016, subject to customary closing conditions, and to be immaterial to Boston Scientific earnings per share (EPS) in 2016 and 2017 on an adjusted and GAAP basis.</description><guid isPermaLink="false">yahoo_finance/3347114646</guid><pubDate>Fri, 02 Dec 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-receives-regulatory-approval-initiate-120000018.html</link><description>[CNW Group] - Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study</description><guid isPermaLink="false">yahoo_finance/3247244788</guid><pubDate>Mon, 28 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-receives-regulatory-approval-initiate-120000300.html</link><description>[PR Newswire] - VANCOUVER, Nov. 28, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced it has received both regulatory and ethics committee approval to initiate the Tiara&#8482; Transcatheter Mitral Valve Replacement Study (TIARA II) in Italy. TIARA II is a 115 patient, non-randomized, prospective clinical study evaluating the safety and performance of the Tiara&#8482; Transcatheter Mitral Valve with the Tiara&#8482; Transapical Delivery System (Tiara&#8482;). With these critical approvals now in place, it is expected that the first Italian TIARA II clinical study site will be initiated before year end, with first enrollment anticipated early in the new year. Approvals in additional geographies are expected in the first quarter of 2017.</description><guid isPermaLink="false">yahoo_finance/334527316</guid><pubDate>Mon, 28 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Neovasc Announces Dismissal of Class Action Lawsuit</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-announces-dismissal-class-action-131400128.html</link><description>[PR Newswire] - The Court ruled in favor of the Company and its officers on all claims and ordered the entire case closed. The Company is not aware as to whether, and presently cannot foresee whether, the plaintiff will appeal the dismissal of his claims or will file any post-dismissal motions. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products in development include the Tiara&#8482;, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer&#8482; for the treatment of refractory angina.</description><guid isPermaLink="false">yahoo_finance/1057794989</guid><pubDate>Wed, 23 Nov 2016 13:14:00 GMT</pubDate></item><item><title>Neovasc Announces Dismissal of Class Action Lawsuit</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/neovasc-announces-dismissal-class-action-131400799.html</link><description>[CNW Group] - Neovasc Announces Dismissal of Class Action Lawsuit</description><guid isPermaLink="false">yahoo_finance/736078663</guid><pubDate>Wed, 23 Nov 2016 13:14:00 GMT</pubDate></item><item><title>Research Reports Initiated on Healthcare Stocks Titan Medical, CRH Medical, Neovasc, and LED Medical Diagnostics</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://news.investornetwork.com/2016/11/21/research-reports-initiated-on-healthcare-stocks-titan-medical-crh-medical-neovasc-and-led-medical-diagnostics/?1=1&amp;1479735998</link><description /><guid isPermaLink="false">yahoo_finance/4245923463</guid><pubDate>Mon, 21 Nov 2016 13:46:38 GMT</pubDate></item></channel></rss>